The Latest “Buzz on the Street” Show: Featuring MediPharm Labs (TSX-V: LABS) (OTCQX: MEDIF) Purchase Agreements

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “MediPharm Labs Secures 9,000 KG of Dried Cannabis Adding Substantial Private Label Cannabis Extract Production.”

MediPharm Labs Corp. (TSX-V: LABS) (OTCQX: MEDIF) (FSE: MLZ) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its wholly owned subsidiary, MediPharm Labs Inc., has entered into purchase agreements to secure a substantial 9,000 KG of dried cannabis supply from multiple cultivators in the last three weeks in June. In addition to MediPharm Labs’ ongoing procurement of cannabis biomass for existing contracts, this bulk purchase is expected to contribute to increased production for future sales and position the Company to meet the mandatory minimum monthly volume requirements to win new large white-label contracts.

Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from being built to cGMP (current Good Manufacturing Practices) and ISO standard-built clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-like cannabis oil and concentrates for advanced derivative products.

Cannabis has emerged as a global and disruptive market over recent year due to a group of the countries moving towards legalization. Notably, Canada’s legalization of adult-use marked a historic milestone within the cannabis industry as it became just the second country and the first G-7 nation to fully legalize cannabis. However, most analysts have diverted their attention towards the U.S. because of the opportunities available within the region. The U.S. has not federally legalized cannabis as of yet but has granted states their own jurisdiction whether to legalize cannabis or not. Now, more than half of the U.S. has legalized cannabis for medicinal applications, while a little over a fifth have legalized its recreational use. While the U.S. has not federally legalized either medical or recreational cannabis, it is still the largest market within the global market space. The U.S. remains as the global cannabis industry driver because of its early adoption, dating back to 1996 when California became the first state to legalize medical cannabis. Moreover, Colorado and Washington made remarkable progress when the two states became the first to ever legalize recreational cannabis in 2014. Since then, the two states have collectively delivered billions of dollars annually off of cannabis sales. Recently, Illinois became the 11th state to legalize cannabis, joining states such as CaliforniaVermont and Michigan in a cohort growing partnership. With Illinois’ passage, more states, including New Jersey and New York, are expected to follow in the near future. Barclays analysts have speculated that if the U.S. cannabis market was legalized today, it could be worth roughly USD 28 Billion. Furthermore, Barclays predicts that the market will grow to USD 41 Billion by 2028 on a pre-tax basis. Barclays compiled the data from a 2017 survey that indicated that approximately 26 million Americans above the age of 12 “were users of marijuana,” or nearly 10% of the total U.S. population. 

The U.S. cannabis market was primarily driven by the sharp rise in users among the ages of 18 to 25. However, other age groups have witnessed a steady increase, particularly among the older generation. Among the younger generation, many consumers may be using cannabis for recreational purposes, while on the other hand, the older generation may prefer cannabis for its therapeutic benefits. Nevertheless, both demographics are seeing a large demand for newer products. For instance, concentrates have become increasingly popular due to their potency and immediate effectiveness. Colorado has witnessed its flower sales substantially fall since it legalized adult-use back in 2014. During its first year, flower sales dominated 67% of Colorado’s total cannabis sales. However, in 2018, flower sales declined to 44% while the concentrates market filled the gap, growing from 15% to 31%. Concentrates are products made from the cannabis plant itself, but which have been thoroughly processed in order to isolate the potent and desirable parts of the plant. Predominantly, oils have grown to become one of the most popular methods of cannabis consumption as they can come in various forms such as CBD oil, THC oil, vaporizer cartridges, and consumable oils. Many consumers are beginning to prefer oils because of their potency as well as versatility. Primarily, frequent and medical users are mainly attracted to stronger products and while cannabis bud potency can usually range from 10% to 25% THC levels, concentrates are typically made to range from 50% to 80%, with some exceeding limits of 90% THC. “Legalization brings a lot of opportunities, including many that are unexpected. One of the biggest areas for expansion is cannabis oil,” according to Scott McGovern, Founder of Blocklr & Growth Nuts. “Despite the rising popularity of cannabis oil, it’s still a relatively undeveloped market because of how it’s produced. Technically, cannabis oil is what you get when you extract a concentrated oil from the marijuana or hemp plant. THC and CBD oil are technically in the same category because they’re produced with the same type of equipment.”

For more information, please visit: MediPharm Labs Corp.

For more corporate news on MediPharm Labs Corp., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

3 Comments
  1. Tom Watson 4 weeks ago
    Reply

    concentrated cannabis oil is a godsend for patients with chronic illness that want to receive relief without the use of addictive opioids.

    • Zack Clayton 3 weeks ago
      Reply

      I think the issue with cannabis oil (apart from its legality…) is the dosage… Some patients are taking too much or too little….

  2. Sue Letwin 4 weeks ago
    Reply

    I think microdosing of cannabis is important research to do for medical patients. Many Lyme patients begin with dosage as low as 2.5 mg with positive benefit. 14-22 mg huge amount for me that I’ve worked up to. HC proposing 10 mg edibles

Leave a Comment

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For medipharm labs corporation, financial and corporate news dissemination, FinancialBuzz.com expects to be compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com..